SBIR-STTR Award

Tuned stem cell extracellular vesicles as a novel chronic wound therapeutic
Award last edited on: 3/2/2021

Sponsored Program
SBIR
Awarding Agency
NIH : NIA
Total Award Amount
$2,220,091
Award Phase
2
Solicitation Topic Code
NIA
Principal Investigator
Yolanda R Leacurrie

Company Information

Zen-Bio Inc (AKA: ZenBio Inc.)

3200 East Highway 54 Suite 100
Research Triangle Pa, NC 27709
   (919) 547-0692
   information@zen-bio.com
   www.zen-bio.com
Location: Single
Congr. District: 04
County: Durham

Phase I

Contract Number: 1R43AG058351-01
Start Date: 9/15/2017    Completed: 8/31/2018
Phase I year
2017
Phase I Amount
$223,180
The elderly population is rapidly increasing worldwide and those over 60 years old are expected to comprise 20% of the total population by 2050. These demographic changes will focus healthcare needs on those conditions more prevalent in the elderly. Chronic wounds, such as venous leg ulcers, pressure ulcers and diabetic ulcers are over-represented in the elderly population and even now present a significant healthcare burden. These conditions impact approximately 6.5 million patients annually with a cost to the health care system of over $25B. Rarely occurring in the young, the healing of these chronic wounds is confounded by age-related factors such as reduced blood flow, dermal atrophy, increased inflammation and reduced growth factor responses. The high recurrence rate and failure to respond to current therapies indicates the need for improved regenerative therapeutics that can overcome many of the age-associated defects in the wound healing process. Stem cell therapies represent a compelling means of tissue repair and have demonstrated wound healing and soft tissue regeneration in animal models. However, the intuitive concept that therapeutic stem cells engraft and differentiate at sites of tissue damage is not well supported given the low numbers of cells retained over time at application sites in vivo. This suggests that their mechanisms of action occur through paracrine modalities such as secretion of bioactive vesicles, including exosomes. Hence, exploiting stem cell-derived exosomes as a biologic-derived therapy, rather than delivering transient stem cells to treat chronic wounds, is an enticing approach. Secreted extracellular vesicles (EVs), such as exosomes, are packed with potent pro-repair proteins and RNA cargos that are both cell type- specific, as well as, differentially produced and secreted according to the cellular environment. Based on our compelling preliminary data, this Phase I proof-of-concept study will demonstrate that critical ex vivo environmental cues can tune stem cell-derived EVs to be pro-healing and that pro-healing EVs are a valid chronic wound therapeutic. We will achieve these goals by the following Aims: 1) manipulate the bioreactor environment to generate differential extracellular vesicle packaging, 2) in vitro testing of EV-mediated regenerative activities in fibroblasts, keratinocytes and endothelial cells, and 3) in vivo testing of pro-healing EVs in chronic wound healing models. This Phase I research program is designed to provide critical proof-of-concept data demonstrating manufacturing conditions and wound healing properties of stem cell- derived extracellular vesicles. This potential therapeutic has the unique advantage of harnessing the power of stem cells without the need for utilizing complex cell therapies in vivo.

Public Health Relevance Statement:
Project Narrative The elderly are most likely to suffer debilitating and chronic, non-healing wounds. Current therapies are largely ineffective and do not address the complex age-related alterations in the healing process. We plan to exploit stem cell-derived extracellular vesicles as a biologic-derived therapy, leveraging the multifaceted healing properties of stem cells to address this urgent clinical need.

Project Terms:
Address; adult stem cell; Age; age related; aged; Aging; aging population; Animal Model; Atrophic; base; Biological; Biological Assay; biophysical properties; Bioreactors; Blood flow; Cell Count; Cell Proliferation; Cell Therapy; cell type; Cells; Chronic; chronic wound; Clinical; Collagen; Comorbidity; Complex; cost; Cues; Cutaneous; Data; db/db mouse; Decubitus ulcer; Defect; Dermal; design; Diabetes Mellitus; Diabetic ulcer; Effectiveness; Elderly; Endothelial Cells; Ensure; Environment; exosome; extracellular vesicles; Failure; Fibroblasts; Goals; Growth Factor; healing; Healthcare; Healthcare Systems; Heat-Shock Response; High temperature of physical object; Hypoxia; Impaired wound healing; improved; In Vitro; in vitro testing; in vivo; individualized medicine; Inflammation; Inflammatory; Intuition; Investigation; Keratin; keratinocyte; Leg Ulcer; Longevity; Mediating; migration; Modality; Modeling; Modification; Monitor; mouse model; Mus; neovascularization; non-healing wounds; novel; Obesity; paracrine; Patients; Phase; Population; Prevalence; Process; Production; programs; Property; Proteins; Recurrence; regenerative; regenerative therapy; repaired; Reporting; Research; Resolution; response; RNA; Site; soft tissue; stem cell biology; stem cell therapy; Stem cells; System; Testing; Therapeutic; Time; tissue regeneration; tissue repair; Tissues; Varicose Ulcer; Venous; Vesicle; wound; wound closure; Wound Healing

Phase II

Contract Number: 2R44AG058351-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2019
(last award dollars: 2020)
Phase II Amount
$1,996,911

The elderly population is rapidly increasing worldwide and those over 60 years old are expected to comprise 20% of the total population by 2050. These demographic changes will focus healthcare needs on those conditions more prevalent in the elderly. Chronic wounds, such as venous leg ulcers, pressure ulcers and diabetic ulcers are over-represented in the elderly population and even now present a significant healthcare burden. These conditions impact approximately 6.5 million patients annually with a cost to the health care system of over $25B. Rarely occurring in the young, the healing of these chronic wounds is confounded by age-related factors such as reduced blood flow, dermal atrophy, increased inflammation and reduced growth factor responses. The high recurrence rate and failure to respond to current therapies indicates the need for improved regenerative therapeutics that can overcome many of the age-associated defects in the wound healing process. Stem cell therapies represent a compelling means of tissue repair and have demonstrated wound healing and soft tissue regeneration in animal models. However, the intuitive concept that therapeutic stem cells engraft and differentiate at sites of tissue damage is not well supported given the low numbers of cells retained over time at application sites in vivo. This suggests that their mechanisms of action occur through paracrine modalities such as secretion of bioactive vesicles, including exosomes. Hence, exploiting stem cell-derived exosomes as a biologic-derived therapy, rather than delivering transient stem cells to treat chronic wounds, is an enticing approach. Secreted extracellular vesicles (EVs), such as exosomes, are packed with potent pro-repair proteins and RNA cargos that are both cell type- specific, as well as, differentially produced and secreted according to the cellular environment. Based on our successful Phase I project, this Phase II program will continue the development and manufacturing of stem cell-derived EVs specifically produced as a chronic wound therapeutic. We will achieve this goal by the following Aims: 1) Optimize the production of selectively-modified hASC EVs for chronic wound healing, 2) In vivo testing of EVs in chronic wound models to establish optimal dosing and route of administration, and 3) Initiate IND enabling studies. This Phase II research program is designed to identify an optimal manufacturing method of bioactive EVs with in vitro and in vivo efficacy and potency, minimal toxicity and strong clinical and translational potential for the treatment of age-related chronic wounds towards a future IND submission. This potential therapeutic has the unique advantage of harnessing the power of stem cells without the need for utilizing complex cell therapies.

Public Health Relevance Statement:
Project Narrative The elderly are most likely to suffer debilitating and chronic, non-healing wounds. Current therapies are largely ineffective and do not address the complex age-related alterations in the healing process. We plan to exploit stem cell-derived extracellular vesicles as a biologic-derived therapy, leveraging the multifaceted healing properties of stem cells to address this urgent clinical need.

Project Terms:
Abnormal Cell; Address; adult stem cell; Affinity; Age; age related; aged; Aging; aging population; Allogenic; Animal Model; Atrophic; base; Beds; Biological; Bioreactors; Blood Chemical Analysis; Blood flow; Cell Count; Cell Therapy; cell type; Cells; Characteristics; Chronic; chronic wound; Clinical; Comorbidity; Complex; cost; Cutaneous; db/db mouse; Decubitus ulcer; Defect; Dermal; design; Development; Diabetes Mellitus; Diabetic ulcer; Dose; drug discovery; Effectiveness; Elderly; Endotoxins; Environment; exosome; extracellular vesicles; Failure; Freezing; Future; Genotype; Goals; Growth Factor; healing; Healthcare; Healthcare Systems; Heat-Shock Response; Hematology; Histopathology; Human; Immune response; Immunocompetent; Impaired wound healing; improved; In Vitro; in vivo; in vivo evaluation; Inflammation; Injections; Intuition; Leg Ulcer; Life; Lipids; Longevity; Measures; Methods; Mixed Lymphocyte Culture Test; Modality; Modeling; Monitor; mouse model; Mus; non-healing wounds; novel; Nucleic Acids; Obesity; Organ; paracrine; Particle Size; Patients; Phase; Phenotype; platelet-derived growth factor BB; Population; Prevalence; Process; Production; programs; Property; Proteins; Recurrence; Regenerative Medicine; regenerative therapy; Renal function; repaired; Research; Resolution; response; RNA; Route; Site; soft tissue; stem cell biology; stem cell therapy; Stem cells; Sterility; Stress; System; Therapeutic; Time; tissue regeneration; tissue repair; Tissues; Topical application; Toxic effect; Varicose Ulcer; Venous; Vesicle; wound; wound closure; Wound Healing